| Name | Title | Contact Details |
|---|
Cayenne Medical is a Scottsdale, AZ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Triad Group is a Hartland, WI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Profusa, Inc. is leading the development of a new generation of biologically integrated sensors that empowers an individual with the ability to continuously monitor their unique body chemistry in unprecedented ways to transform the management of personal health and disease. Overcoming the bodys response to foreign material, the companys technology enables the development of minute bioengineered sensors that become one with the body to detect and transmit clinical-grade data for personal and medical use.
DermaMed Solutions helps spa owners, dermatologists, plastic surgeons and other skin care and medical professionals expand their practices to include additional services. Entrepreneur Roger Parkin founded our company in 1998. Inspiration came when an aesthetician suggested he develop a quieter microdermabrasion machine. The result was MegaPeel®. Besides being quieter than similar devices, our microdermabrasion system was smaller, was easier to use and reduced troublesome vibrations.
BioSig Technologies, Inc. (NASDAQ: BSGM) is a medical device company that is developing a proprietary biomedical signal processing technology platform to address an unmet technology need in the rapidly growing $4.6+ billion electrophysiology (EP) marketplace. Led by a proven management team, world-class Board of Directors and Scientific Advisory Board, Los Angeles-based BioSig Technologies is preparing to commercialize its PURE EP™ System. The PURE EP™System is a surface electrocardiogram (ECG) and intracardiac multichannel recording and analysis system designed to assist electrophysiologists in making crucial clinical decisions in real-time by acquiring and displaying high-fidelity cardiac signal recordings even at undetectable levels (until now) with high accuracy to help identify appropriate catheter ablation targets - areas of tissue to destroy that create a heart rhythm disturbance (arrhythmia). BioSig aims to deliver technology to improve upon catheter ablation treatments for the prevalent and potentially deadly arrhythmias, Atrial Fibrillation and Ventricular Tachycardia. PURE EP™ System is an innovative platform, offering potential benefits over current technologies including increased accuracy, reduced noise and interference, clinical information previously not available and potential elimination of the need for repeat procedures. BioSig has partnered with Minnetronix on technology development and has received FDA 510(k) clearance for the PURE EP™ System in August 2018. BioSig Technologies, Inc. is a Nasdaq company: NASDAQ:BSGM.